EcoDrugPlus

Solute Carrier Family 18 Member 2

Ensembl ID : ENSSLUG00000018702
Gene Symbol: SLC18A2
1 Cross references
214 Possible Orthologues:

Solute Carrier Family 18 Member 2

Ensembl ID : ENSSLUG00000020881
Gene Symbol: SLC18A2
1 Cross references
214 Possible Orthologues:

Solute Carrier Family 22 Member 6-Like

Ensembl ID : ENSSLUG00000008998
Gene Symbol: LOC116064728
3 Cross references
358 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSSLUG00000004646
Gene Symbol: SLC29A1
3 Cross references
210 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSSLUG00000023497
Gene Symbol: SLC5A1
1 Cross references
250 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSSLUG00000020493
Gene Symbol: SLC5A2
1 Cross references
198 Possible Orthologues:

Solute Carrier Family 6 Member 1b

Ensembl ID : ENSSLUG00000010281
Gene Symbol: SLC6A1B
1 Cross references
209 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSSLUG00000021814
Gene Symbol: SLC6A2
1 Cross references
203 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSSLUG00000005214
Gene Symbol: SLC6A3
1 Cross references
166 Possible Orthologues:

Solute Carrier Family 6 Member 4

Ensembl ID : ENSSLUG00000011464
Gene Symbol: SLC6A4
3 Cross references
201 Possible Orthologues:

Solute Carrier Family 6 Member 9

Ensembl ID : ENSSLUG00000017353
Gene Symbol: SLC6A9
1 Cross references
208 Possible Orthologues:

Solute Carrier Family 9 Member A3, Tandem Duplicate 2

Ensembl ID : ENSSLUG00000001676
Gene Symbol: SLC9A3.2
1 Cross references
234 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).